Aquestive Therapeutics names Richard Daly to its board of directors
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
- Bloom Energy shares fall on Oracle project halt
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Stocks fall as higher oil prices, Treasury yields weigh
- Oppenheimer sees AI software winners as focus shifts to ROI
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly
September 29, 2026 7:00 AM EDTAppoints Rich Daly, a life sciences executive with more than 30 years of leadership experience across large pharmaceutical companies, emerging biotechnology companies, and public company boards, to its Board of Directors
WARREN, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (Aquestive or the Company), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Rich Daly to the Companys Board of Directors, effective October 14, 2026. Mr. Daly has three decades of leadership experience in large and small... More
